The rising impact of biomarkers in early clinical development
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
List view / Grid view
Dr Cyril Clarke at ICON Biotech reveals how biomarkers are transforming early-phase clinical trials by offering valuable insights into the safety and efficacy of novel therapies.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
4 April 2025 | By Eurofins Discovery
Join Dr. Francisca Neethling from Eurofins Discovery to explore the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
rBIO is transforming the biosimilar insulin market with a novel biomanufacturing platform designed to reduce production costs while maintaining high-quality standards. CEO Cameron Owen shares how their approach is shaping drug discovery and improving patient access to life-saving treatments.
A government-funded research team has identified focal adhesion kinase (FAK) as a key driver of melanoma metastasis to the brain. This discovery could revolutionise treatment by not only addressing the condition but also preventing its spread to the brain.
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
28 March 2025 | By Drug Target Review
Join this expert-led webinar to discover how lab automation and AI are transforming early preclinical research. Learn how cutting-edge technologies are reshaping lab workflows, improving reproducibility, and fast-tracking drug development from discovery to preclinical validation.
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
In this second part of a two-part series, we continue Sujeegar Jeevanandam’s exploration of the future of AI in drug discovery. We share his vision for transformative AI applications, such as simulating human pharmacokinetics and pharmacodynamics, and offer strategic recommendations for biotechs looking to adopt AI.
Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care.
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.